Cargando…
Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes
(1) Background: Over the past 20 years, monoclonal antibodies have been developed for the treatment of severe asthma, with numerous randomised controlled trials (RCTs) conducted to define their safety and efficacy. The growing availability of biologics, which until now have only been available for T...
Autor principal: | Menzella, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960148/ https://www.ncbi.nlm.nih.gov/pubmed/36836079 http://dx.doi.org/10.3390/jcm12041546 |
Ejemplares similares
-
Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
por: Menzella, Francesco, et al.
Publicado: (2022) -
The clinical profile of benralizumab in the management of severe
eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016) -
Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016) -
Tailored therapy for severe asthma
por: Menzella, Francesco, et al.
Publicado: (2015) -
Targeting eosinophils: severe asthma and beyond
por: Caminati, Marco, et al.
Publicado: (2019)